Interactions of Prednisolone and Other Immunosuppressants Used in Dual Treatment of Systemic Lupus Erythematosus in Lymphocyte Proliferation Assays

Por Kamal, Mohamed A., Jusko, William J.
Publicado em 2004

Role and Relevance of PEPT2 in Drug Disposition, Dynamics, and Toxicity

Por Kamal, Mohamed A., Keep, Richard F., Smith, David E.
Publicado em 2008

Influence of genetic knockout of Pept2 on the in vivo disposition of endogenous and exogenous carnosine in wild-type and Pept2 null mice

Por Kamal, Mohamed A., Jiang, Huidi, Hu, Yongjun, Keep, Richard. F., Smith, David E.
Publicado em 2009

Pharmacodynamic Differentiation of Lorazepam Sleepiness and Dizziness Using an Ordered Categorical Measure

Por Kamal, Mohamed A., Smith, David E., Cook, Jack, Feltner, Douglas, Moton, Allen, Ouellet, Daniele
Publicado em 2010

Assessing Mathematical Models of Influenza Infections Using Features of the Immune Response

Por Dobrovolny, Hana M., Reddy, Micaela B., Kamal, Mohamed A., Rayner, Craig R., Beauchemin, Catherine A. A.
Publicado em 2013

Managing the Combination of Nonalcoholic Fatty Liver Disease and Metabolic Syndrome with Chinese Herbal Extracts in High-Fat-Diet Fed Rats

Por Tan, Yi, Lao, Weiguo, Xiao, Linda, Wang, Zhenzhong, Xiao, Wei, Kamal, Mohamed A., Seale, J. Paul, Qu, Xianqin
Publicado em 2013

Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysis

Por Patel, Kashyap, Rayner, Craig R, Giraudon, Mylène, Kamal, Mohamed A, Morcos, Peter N, Robson, Richard, Kirkpatrick, Carl M
Publicado no Br J Clin Pharmacol (2015)

A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression

Por Kamal, Mohamed A., Gieschke, Ronald, Lemenuel-Diot, Annabelle, Beauchemin, Catherine A. A., Smith, Patrick F., Rayner, Craig R.
Publicado no Antimicrob Agents Chemother (2015)

Investigating Clinically Adequate Concentrations of Oseltamivir Carboxylate in End-Stage Renal Disease Patients Undergoing Hemodialysis Using a Population Pharmacokinetic Approach

Por Kamal, Mohamed A., Lien, Kayla Yi Ting, Robson, Richard, Subramoney, Vishak, Clinch, Barry, Rayner, Craig R., Gibiansky, Leonid
Publicado no Antimicrob Agents Chemother (2015)

Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression

Por Kamal, Mohamed A., Gieschke, Ronald, Lemenuel-Diot, Annabelle, Beauchemin, Catherine A. A., Smith, Patrick F., Rayner, Craig R.
Publicado no Antimicrob Agents Chemother (2016)

Population Pharmacokinetics of Oseltamivir: Pediatrics through Geriatrics

Por Kamal, Mohamed A., Van Wart, Scott A., Rayner, Craig R., Subramoney, Vishak, Reynolds, Daniel K., Bulik, Catharine C., Smith, Patrick F., Bhavnani, Sujata M., Ambrose, Paul G., Forrest, Alan
Publicado em 2013

Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics

Por Kamal, Mohamed A., Smith, Patrick F., Chaiyakunapruk, Nathorn, Wu, David B. C., Pratoomsoot, Chayanin, Lee, Kenneth K. C., Chong, Huey Yi, Nelson, Richard E., Nieforth, Keith, Dall, Georgina, Toovey, Stephen, Kong, David C. M., Kamauu, Aaron, Kirkpatrick, Carl M., Rayner, Craig R.
Publicado no Br J Clin Pharmacol (2017)